GENPF Stock GENIX PHARMACEUTICALS (GENPF, $0.02) was a top quarterly gainer, rising +26.09%

GET DAILY SIGNALS

Get AI intraday signals

GENPF - GENIX PHARMACEUTICALS CORP.

Loading...

Price: $0.0174

Daily change: +$0.0036 (+26.09%)

Daily volume: 68K

3-month price change: +$0.0036 (+26.09%)

Capitalization: $1.1M

Industry: Pharmaceuticals: Generic

GENIX PHARMACEUTICALS (GENPF, $0.02) was one of top quarterly gainers, jumping +2 to $0.02 per share. A.I.dvisor analyzed 221 stocks in the Pharmaceuticals: Generic Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down.

GENPF in downward trend: price may drop because broke its higher Bollinger Band on November 03, 2025

GENPF broke above its upper Bollinger Band on November 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 10 similar instances where the stock broke above the upper band. In of the 10 cases the stock fell afterwards. This puts the odds of success at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GENPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.827). P/E Ratio (0.000) is within average values for comparable stocks, (71.764). GENPF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.856). GENPF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). GENPF's P/S Ratio (1111.111) is very high in comparison to the industry average of (39.291).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENPF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.